135857-20-4

Basic information

• Product Name: 2-(4-FORMYLPHENOXY)ACETAMIDE
• Synonyms: ART-CHEM-BB B000277;2-(4-FORMYLPHENOXY)ACETAMIDE;AKOS B000277;2-(4-formylphenoxy)acetamide(SALTDATA: FREE);2-(4-methanoylphenoxy)ethanamide
• CAS NO: 135857-20-4
• Molecular Formula: C₉H₉NO₃
• Molecular Weight: 179.17
• Mol File: 135857-20-4.mol

Chemical Properties

• Melting Point: 135-137 °C(Solv: water (7732-18-5))
• Boiling Point: 435.6°C at 760 mmHg
• Flash Point: 268.9°C
• Appearance: /
• Density: 1.258g/cm³
• Vapor Pressure: 8.63E-08mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: 2-8°C
• PKA: 15.21±0.40(Predicted)
• CAS DataBase Reference: 2-(4-FORMYLPHENOXY)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-FORMYLPHENOXY)ACETAMIDE(135857-20-4)
• EPA Substance Registry System: 2-(4-FORMYLPHENOXY)ACETAMIDE(135857-20-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 135857-20-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
2-(4-Formylphenoxy)acetamide is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of potential drugs. Its presence in these compounds can contribute to their therapeutic effects and pharmacological profiles.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(4-Formylphenoxy)acetamide is used as a versatile building block for creating a wide range of organic compounds. Its reactivity and structural features make it suitable for various synthetic pathways and the formation of complex organic molecules.
Used in Agrochemical Development:
2-(4-Formylphenoxy)acetamide is also utilized in the development of agrochemicals, where it may serve as a component in the design of new pesticides, herbicides, or other agricultural chemicals, potentially enhancing crop protection and yield.
Used in Enzyme Inhibition Studies:
In medicinal chemistry, this compound is studied for its potential to inhibit certain enzymes. Its use in enzyme inhibition assays helps researchers understand its interaction with biological targets, which could lead to the development of new therapeutic agents.
Used in Drug Candidate Development:
Due to its potential pharmacological properties, 2-(4-Formylphenoxy)acetamide is considered a drug candidate for various conditions. Its exploration in this context is aimed at identifying new treatment options and advancing the understanding of its therapeutic potential.

InChI:InChI=1/C9H9NO3/c10-9(12)6-13-8-3-1-7(5-11)2-4-8/h1-5H,6H2,(H2,10,12)

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 79-07-2 Chloroacetamide 
• 144-48-9 iodacetamide 
• 683-57-8 bromo-acetic acid amide 

Downstream Products

• 371956-62-6 2-amino-4-(4-carbamoylmethoxy)phenyl-3-cyano-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-benzo[b]pyran 
• 902745-30-6 2-(4-carbamoylmethoxy-benzylidene)-malonic acid 
• 873811-55-3 3-(4-carbamoylmethoxy-phenyl)-acrylic acid 
• 1044870-60-1 2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide 
• 930552-50-4 2-(4-((5-chloro-2-oxoindolin-3-ylidene)methyl)phenoxy)acetamide 
• 1100350-28-4 C₂₀H₁₇N₃O₃S 
• 519018-81-6 (E,Z)-2-(4-(2-(1H-benzo[d]imidazol-2-yl)-2-cyanovinyl)phenoxy)acetamide 
• 1314881-68-9 (E,Z)-2-(4-(2-(4-chloro-1H-benzo[d]imidazol-2-yl)-2-cyanovinyl)phenoxy)acetamide 
• 1314881-69-0 (E,Z)-2-(4-(2-cyano-2-(4-methoxy-1H-benzo[d]imidazol-2-yl)vinyl)phenoxy)acetamide 
• 1314881-70-3 (E,Z)-2-(4-(2-cyano-2-(4,5-dimethyl-1H-benzo[d]imidazol-2-yl)vinyl)phenoxy)acetamide 
• 471921-91-2 2-(4-(2-cyano-2-(5,6-dimethyl-1H-benzo[d]imidazol-2-yl)vinyl)phenoxy)acetamide 
• 335208-79-2 2-[4-(1-amino-2,4-dicyanopyrido[1,2-a]benzimidazol-3-yl)phenoxy]acetamide 
• 1314881-62-3 2-(4-(1-amino-2,4-dicyano-6-methylbenzo[4,5]imidazo[1,2-a]pyridin-3-yl)phenoxy)acetamide 
• 1314881-63-4 2-(4-(1-amino-6-chloro-2,4-dicyanobenzo[4,5]imidazo[1,2-a]pyridin-3-yl)phenoxy)acetamide 

Relevant articles and documents

A process for the preparation of intermediates palestinian multi-past fragrance acetate

The invention discloses a method for preparing a bazedoxifene acetate intermediate. The preparation method comprises the following steps: 1, condensing 4-hydroxybenzaldehyde S01 and alkylate S02 to prepare a 4-formyl phenoxy derivative M01; 2, performing

Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents

A series of 5-(carbamoylmethoxy)benzylidene-2-oxo/thioxo-4-thiazolidinone derivatives (6-9) were synthesized as inhibitors of aldose reductase (AR), enzyme which plays a crucial role in the development of diabetes complications as well as in the inflammat

Synthesis and biological evaluation of 2-Phenoxyacetamide analogues, a novel class of potent and selective monoamine oxidase inhibitors

Monoamine oxidases (EC 1.4.3.4; MAOs), a family of FAD-containing enzymes, is an important target for antidepressant drugs. In this paper, a series of 2-phenoxyacetamide analogues were synthesized, and their inhibitory potency towards monoamine oxidases A (MAO-A) and B (MAO-B) were evaluated using enzyme and cancer cell lysate. 2-(4-Methoxyphenoxy)acetamide (compound 12) (SI = 245) and (2-(4-((prop-2- ynylimino)methyl)phenoxy)acetamide (compound 21) (IC50MAO-A = 0.018 μM, IC50MAO-B = 0.07 μM) were successfully identified as the most specific MAO-A inhibitor, and the most potent MAO-A/-B inhibitor, respectively. The inhibitory activities of these two compounds in living cells were also further evaluated utilizing HepG2 and SHSY-5Y cell lysates.

IMIDAZO [4, 5 - B] PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

Inhibition of γ-secretase by the CK1 inhibitor IC261 does not depend on CK1δ

CK1 and γ-secretase are interesting targets for therapeutic intervention in the treatment of cancer and Alzheimer's disease. The CK1 inhibitor IC261 was reported to inhibit γ-secretase activity. The question is: Does CK1 inhibition directly influence γ-se

HYDRAZONE DERIVATIVE

A compound represented by the following formula (I): wherein R1 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R2 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R3 represents hydrogen, etc.; Ar represents a divalent group derived from aromatic hydrocarbon, etc.; X represents a single bond, linear or branched alkylene having from 1 to 3 carbon atoms which may have a substituent, etc.; and G represents halogen, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc., a salt thereof or a solvate thereof; and an agent for inhibiting aggregation and/or deposition of an amyloid protein or an amyloid-like protein, which comprises the compound, a salt thereof or a solvate thereof

Competitive formation of β-amino acids, propenoic, and ylidenemalonic acids by the Rodionov reaction from malonic acid, aldehydes, and ammonium acetate in alcoholic medium

The Rodionov reaction of 49 available aliphatic and aromatic aldehydes with malonic acid and ammonium acetate in alcoholic medium, resulting in formation of β-amino acids, propenoic, and ylidenemalonic acids, was studied. Certain regioselectivity regularities of the reaction were revealed. Among the variety of ketones studied, cyclohexanone is the only whose reaction yields a β-amino acid. Unusual dehydrofluorination of 6-chloro-2-fluorocinnamic acid under the Rodionov reaction was discovered. 2005 Pleiades Publishing, Inc.